ACS CAN comments on CY2018 Medicare Physician Fee Schedule proposed rule

In our comments on the CY 2018 Medicare Physician Fee Schedule proposed rule, ACS CAN expressed support for CMS’ proposed changes that would allow federally qualified health centers to provide more care coordination, and urged CMS to provide even more flexibility than proposed. In response to CMS’ request for comments on reimbursement for biosimilar drugs, ACS CAN urged CMS not to adopt any policy that would unintentionally result in prescribing practices inconsistent with the approval status of a biosimilar drug. Finally, ACS CAN also expressed support for the Medicare Diabetes Prevention Program , because many of the program’s interventions will also lower beneficiaries’ risk of developing cancer.